Login
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc.

mazetx.com

What Do They Do?

Develops small-molecule medicines for patients with kidney and metabolic diseases, using genetic research to identify drug targets and guide development.

How Do They Make Money?

Maze earns revenue by granting licenses to drug programs to biotechnology companies; agreements can bring upfront payments, milestone payments, and royalties tied to licensed products’ sales.

FY2025 revenue

Who Are Their Customers?

Biotechnology companies obtain licenses to Maze’s drug programs through license agreements.

Do Revenues Turn Into Profits?

No. It lost $131.1M in FY2025.

Operating income, FY2025
−1213% of revenue
▼ Turned to a loss vs FY2024 ($57.6M, 34%)
Net income, FY2025
−1113% of revenue
▼ Turned to a loss vs FY2024 ($52.2M, 31%)
Free cash flow, FY2025
−957% of revenue
▼ Turned to a loss vs FY2024 ($74.8M, 45%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −59% (Loss)
vs −$30.1M in Q3 FY2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support